Drug Information
Drug (ID: DG00045) and It's Reported Resistant Information
Name |
Sirolimus
|
||||
---|---|---|---|---|---|
Synonyms |
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
Click to Show/Hide
|
||||
Indication |
In total 3 Indication(s)
|
||||
Structure | |||||
Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(2 diseases)
Breast cancer [ICD-11: 2C60]
[2]
Chordoma [ICD-11: 2B5J]
[3]
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug
(2 diseases)
Bladder cancer [ICD-11: 2C94]
[4]
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
[5]
|
||||
Target | PI3K/AKT/mTOR pathway (PAm pathway) | NOUNIPROTAC | [1] | ||
Serine/threonine-protein kinase mTOR (mTOR) | MTOR_HUMAN | [1] | |||
Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
Formula |
C51H79NO13
|
||||
IsoSMILES |
C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
|
||||
InChI |
1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
|
||||
InChIKey |
QFJCIRLUMZQUOT-HPLJOQBZSA-N
|
||||
PubChem CID | |||||
ChEBI ID | |||||
TTD Drug ID | |||||
VARIDT ID | |||||
INTEDE ID | |||||
DrugBank ID |
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
EADR: Epigenetic Alteration of DNA, RNA or Protein
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Mature B-cell neoplasms/lymphoma [ICD-11: 2A85]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Growth arrest specific 5 (GAS5) | [5] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Disease | Mantle cell lymphoma [ICD-11: 2A85.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
mTOR signaling pathway | Regulation | hsa04150 | ||
In Vitro Model | Z138 cells | Peripheral blood | Homo sapiens (Human) | CVCL_B077 |
Jeko-1 cells | Blood | Homo sapiens (Human) | CVCL_1865 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Nigrosin exclusion analysis | |||
Mechanism Description | Small interfering RNAs (sirRNAs) targeting GAS5 protect the cell viability and proliferation of jeko-1 and z-138 cells from the inhibitory effects of mTOR inhibitors result in rapamycin resistance. | |||
Key Molecule: Growth arrest specific 5 (GAS5) | [5] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Disease | Mantle cell lymphoma [ICD-11: 2A85.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Inhibition | hsa04210 | |
Cell proliferation | Activation | hsa05200 | ||
mTOR signaling pathway | Regulation | hsa04150 | ||
In Vitro Model | Z138 cells | Peripheral blood | Homo sapiens (Human) | CVCL_B077 |
Jeko-1 cells | Blood | Homo sapiens (Human) | CVCL_1865 | |
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
Nigrosin exclusion analysis | |||
Mechanism Description | Small interfering RNAs (sirRNAs) targeting GAS5 protect the cell viability and proliferation of jeko-1 and z-138 cells from the inhibitory effects of mTOR inhibitors result in rapamycin resistance. |
Osteosarcoma [ICD-11: 2B51]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-410 | [1] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Autophagy-related protein 16-1 (ATG16L1) | [1] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | HEK293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 |
MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
HFob 1.19 | Bone | Homo sapiens (Human) | CVCL_3708 | |
Experiment for Molecule Alteration |
Luciferase reporter assay; Western blot analysis | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | microRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma, miR410 directly decreased ATG16L1 expression by targeting its 3'-untranslated region. |
Chordoma [ICD-11: 2B5J]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Y-box-binding protein 1 (YBX1) | [3] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Chordoma [ICD-11: 2B5J.0] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | EGFR/AKT signaling pathway | Regulation | hsa04012 | |
Cell invasion | Activation | hsa05200 | ||
In Vitro Model | Chordoma tissue | N.A. | ||
In Vivo Model | NOD/SCID/IL2Rgamma null (NOG) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
CCK-8 assay | |||
Mechanism Description | YBX1 regulated protein expression of pEGFR, pAKT and its downstream target genes that influenced cell apoptosis, cell cycle transition and cell invasion. YBX1 activated the EGFR/AKT pathway in chordoma and YBX1-induced elevated expression of key molecules in the EGFR/AKT pathway were downregulated by EGFR and AKT pathway inhibitors. These in vitro results were further confirmed by in vivo data. These data showed that YBX1 promoted tumorigenesis and progression in spinal chordoma via the EGFR/AKT pathway. YBX1 might serve as a prognostic and predictive biomarker, as well as a rational therapeutic target, for chordoma. |
Breast cancer [ICD-11: 2C60]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: Serine/threonine-protein kinase mTOR (mTOR) | [2] | |||
Molecule Alteration | Missense mutation | p.F2108L |
||
Resistant Disease | Breast cancer [ICD-11: 2C60.3] | |||
Experimental Note | Identified from the Human Clinical Data | |||
Cell Pathway Regulation | PIk3CA/AKT/mTOR signaling pathway | Activation | hsa04211 | |
In Vitro Model | MCF-7 cells | Breast | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-468 cells | Breast | Homo sapiens (Human) | CVCL_0419 | |
Experiment for Molecule Alteration |
Integrated Mutation Profiling of Actionable Cancer Targets assay; Sanger sequencing assay | |||
Experiment for Drug Resistance |
CellTiter-Glo luminescent cell viability assay | |||
Mechanism Description | The clinical relevance of these mutations is supported by a case report of a patient who acquired the identical F2108L mTOR mutation after relapse under everolimus treatment. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Ubiquitin protein ligase E3 component n-recognin 5 (UBR5) | [6] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Breast cancer [ICD-11: 2C60.3] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | MCF-7 cells | Breast | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-436 cells | Breast | Homo sapiens (Human) | CVCL_0623 | |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
MTS assay | |||
Mechanism Description | High nuclear EDD expression in a cohort of 151 women with serous ovarian carcinoma was associated with an increased risk of disease recurrence following first-line chemotherapy, and siRNA-knockdown of EDD gene expression partially restored cisplatin sensitivity in cisplatin-resistant ovarian cancer cells in vitro. Loss of EDD induced cell-cycle arrest at G1 through upregulation of tumour suppressor p53 and p21 proteins in osteosarcoma cells in vitro. |
Cervical cancer [ICD-11: 2C77]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-mir-218 | [7] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Disease | Cervical cancer [ICD-11: 2C77.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
mTOR signaling pathway | Inhibition | hsa04150 | ||
In Vitro Model | Hela cells | Cervix uteri | Homo sapiens (Human) | CVCL_0030 |
Siha cells | Cervix uteri | Homo sapiens (Human) | CVCL_0032 | |
Caski cells | Uterus | Homo sapiens (Human) | CVCL_1100 | |
C33A cells | Uterus | Homo sapiens (Human) | CVCL_1094 | |
In Vivo Model | Mouse bearing cervical cancer model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | microRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor and reducing the level of Rictor in cervical cancer. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Rapamycin-insensitive companion of mTOR (RICTOR) | [7] | |||
Molecule Alteration | Expression | Down-regulation |
||
Sensitive Disease | Cervical cancer [ICD-11: 2C77.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
mTOR signaling pathway | Inhibition | hsa04150 | ||
In Vitro Model | Hela cells | Cervix uteri | Homo sapiens (Human) | CVCL_0030 |
Siha cells | Cervix uteri | Homo sapiens (Human) | CVCL_0032 | |
Caski cells | Uterus | Homo sapiens (Human) | CVCL_1100 | |
C33A cells | Uterus | Homo sapiens (Human) | CVCL_1094 | |
In Vivo Model | Mouse bearing cervical cancer model | Mus musculus | ||
Experiment for Molecule Alteration |
RT-qPCR | |||
Experiment for Drug Resistance |
MTT assay; Flow cytometry assay | |||
Mechanism Description | microRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor and reducing the level of Rictor in cervical cancer. |
Prostate cancer [ICD-11: 2C82]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: Growth arrest specific 5 (GAS5) | [8] | |||
Molecule Alteration | Expression | Up-regulation |
||
Sensitive Disease | Prostate cancer [ICD-11: 2C82.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell proliferation | Inhibition | hsa05200 | |
In Vitro Model | DU-145 cells | Prostate | Homo sapiens (Human) | CVCL_0105 |
LNCaP cells | Prostate | Homo sapiens (Human) | CVCL_0395 | |
PC3 cells | Prostate | Homo sapiens (Human) | CVCL_0035 | |
22RV1 cells | Prostate | Homo sapiens (Human) | CVCL_1045 | |
PNT2C2 cells | Prostate | Homo sapiens (Human) | CVCL_4889 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
GAS5 assay; MTS assay | |||
Mechanism Description | First generation mTORC1, combined mTORC1/mTORC2 and dual PI3k/mTOR inhibitors all increased cellular GAS5 levels and inhibited culture growth in androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in androgen-independent (PC-3 and DU 145) cell lines. The latter exhibited low endogenous GAS5 expression, and GAS5 silencing in LNCaP and 22Rv1 cells decreased the sensitivity to mTOR inhibitors, whereas transfection of GAS5 LncRNA sensitized PC-3 and DU 145 cells to these agents. |
Bladder cancer [ICD-11: 2C94]
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Key Molecule: hsa-miR-582-5p | [4] | |||
Molecule Alteration | Expression | Up-regulation |
||
Resistant Disease | Bladder cancer [ICD-11: 2C94.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
In Vitro Model | 5637 cells | Bladder | Homo sapiens (Human) | CVCL_0126 |
EJ cells | Bladder | Homo sapiens (Human) | CVCL_UI82 | |
J82 cells | Bladder | Homo sapiens (Human) | CVCL_0359 | |
SV-HUC-1 cells | Bladder | Homo sapiens (Human) | CVCL_3798 | |
T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
HT1376 cells | Bladder | Homo sapiens (Human) | CVCL_1292 | |
In Vivo Model | BALB/c nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | UCA1 knockdown suppresses growth, migration, and invasion of T24 and 5637 cells via derepression of miR-582-5p and ATG7 was downregulated by UCA1 shRNA and upregulated by miR-582-5p inhibitor. | |||
Key Molecule: Urothelial cancer associated 1 (UCA1) | [4] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Disease | Bladder cancer [ICD-11: 2C94.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
In Vitro Model | 5637 cells | Bladder | Homo sapiens (Human) | CVCL_0126 |
EJ cells | Bladder | Homo sapiens (Human) | CVCL_UI82 | |
J82 cells | Bladder | Homo sapiens (Human) | CVCL_0359 | |
SV-HUC-1 cells | Bladder | Homo sapiens (Human) | CVCL_3798 | |
T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
HT1376 cells | Bladder | Homo sapiens (Human) | CVCL_1292 | |
In Vivo Model | BALB/c nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | UCA1 knockdown suppresses growth, migration, and invasion of T24 and 5637 cells via derepression of miR-582-5p and ATG7 was downregulated by UCA1 shRNA and upregulated by miR-582-5p inhibitor. | |||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Ubiquitin-like modifier-activating enzyme ATG7 (ATG7) | [4] | |||
Molecule Alteration | Expression | Down-regulation |
||
Resistant Disease | Bladder cancer [ICD-11: 2C94.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell viability | Activation | hsa05200 | |
In Vitro Model | 5637 cells | Bladder | Homo sapiens (Human) | CVCL_0126 |
EJ cells | Bladder | Homo sapiens (Human) | CVCL_UI82 | |
J82 cells | Bladder | Homo sapiens (Human) | CVCL_0359 | |
SV-HUC-1 cells | Bladder | Homo sapiens (Human) | CVCL_3798 | |
T24 cells | Bladder | Homo sapiens (Human) | CVCL_0554 | |
HT1376 cells | Bladder | Homo sapiens (Human) | CVCL_1292 | |
In Vivo Model | BALB/c nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Western blot analysis | |||
Experiment for Drug Resistance |
CCK8 assay | |||
Mechanism Description | UCA1 knockdown suppresses growth, migration, and invasion of T24 and 5637 cells via derepression of miR-582-5p and ATG7 was downregulated by UCA1 shRNA and upregulated by miR-582-5p inhibitor. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.